Risk of Respiratory Depression with Non-Opioid CNS Depressant Combinations
Understanding the Risks of Individual Medications and Combinations
- Cyclobenzaprine is a centrally-acting muscle relaxant that contributes to CNS depression, and co-prescribing muscle relaxants with other CNS depressants may increase risk of patient harm, according to the 2020 Annals of Emergency Medicine guidelines 1
- The combination of non-opioid sedatives shows additive CNS depression effects, and the American College of Emergency Physicians notes that coadministration of these medications increases the risk of CNS depression 1
Quantifying the Actual Risk of Non-Opioid CNS Depressant Combinations
- In procedural sedation studies using multiple CNS depressants (without opioids), minor respiratory events occurred in 10-20% of patients, typically responding to verbal stimulation or repositioning, as reported in the Annals of Emergency Medicine 2, 3, 6
- Serious adverse events requiring bag-valve-mask ventilation or intubation were rare, occurring in 0-2% of cases, according to the Annals of Emergency Medicine 2, 3, 6
Patient-Specific Risk Factors to Assess
- Elderly patients have increased susceptibility due to limited cardiopulmonary reserve, as noted in the Annals of Emergency Medicine 4
Clinical Monitoring Recommendations
- Monitor for progressive sedation, as sedation often precedes respiratory depression, and assess oxygen saturation if the patient appears oversedated, as recommended by the National Comprehensive Cancer Network 7
Common Pitfalls to Avoid
- Do not equate this combination's risk with opioid-benzodiazepine combinations, which carry black box warnings and dramatically higher mortality, as stated in the Annals of Emergency Medicine and the Journal of the National Comprehensive Cancer Network 1, 7
- Do not assume all CNS depressant combinations carry equal risk—the presence or absence of opioids fundamentally changes the risk profile, according to the Annals of Emergency Medicine 1, 5